KYMR - Kymera Therapeutics, Inc. Stock Price, Fair Value and News

$65.98+1.71 (+2.66%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

KYMR Price Action

Last 7 days

-2.8%

Last 30 days

10.5%

Last 90 days

56.4%

Trailing 12 Months

40.7%

KYMR RSI Chart

KYMR Valuation

Market Cap

4.7B

Price/Earnings (Trailing)

-16.09

Price/Sales (Trailing)

108.55

Price/Free Cashflow

-20.62

KYMR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

KYMR Fundamentals

KYMR Revenue

Revenue (TTM)

43.7M

Rev. Growth (Yr)

-26.12%

Rev. Growth (Qtr)

-75.91%

KYMR Earnings

Earnings (TTM)

-295.1M

Earnings Growth (Yr)

-31.51%

Earnings Growth (Qtr)

-7.26%

KYMR Profitability

Return on Equity

-31.19%

Return on Assets

-26.78%

Free Cashflow Yield

-4.85%

KYMR Investor Care

Shares Dilution (1Y)

11.09%

Diluted EPS (TTM)

-3.6

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	58.9M	44.7M	43.7M	0
2024	79.4M	88.5M	87.6M	47.1M
2023	46.7M	51.7M	46.8M	78.6M
2022	63.8M	56.7M	46.0M	46.8M
2021	49.3M	64.5M	70.3M	72.8M
2020	10.7M	18.5M	26.3M	34.0M
2019	0	0	0	2.9M

Get all data in R, Python etc through our Historical Stock Data APIs

About Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

CEO	Dr. Nello Mainolfi M.D., Ph.D.
WEBSITE	kymeratx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	181

Kymera Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Kymera Therapeutics, Inc.? What does KYMR stand for in stocks?

KYMR is the stock ticker symbol of Kymera Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Kymera Therapeutics, Inc. (KYMR)?

As of Wed Dec 03 2025, market cap of Kymera Therapeutics, Inc. is 4.75 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KYMR stock?

You can check KYMR's fair value in chart for subscribers.

Is Kymera Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether KYMR is over valued or under valued. Whether Kymera Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Kymera Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KYMR.

What is Kymera Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, KYMR's PE ratio (Price to Earnings) is -16.09 and Price to Sales (PS) ratio is 108.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KYMR PE ratio will change depending on the future growth rate expectations of investors.